R
R. Giuliani
Publications - 7
Citations - 610
R. Giuliani is an academic researcher. The author has contributed to research in topics: Safinamide & Placebo. The author has an hindex of 5, co-authored 7 publications receiving 497 citations.
Papers
More filters
Journal ArticleDOI
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Rupam Borgohain,József Attila Szász,Paolo Stanzione,Chandrashekhar Meshram,Mohit Bhatt,D. Chirilineau,Fabrizio Stocchi,V. Lucini,R. Giuliani,Emma Forrest,P. Rice,R. Anand,M. Illiyas Sahadulla,U. Kardan,B. S. Keshava,A. Kishore,S. S. Kothari,J. M. Krishna Murthy,S. Kumar,P. Kumar Pal,N. Mehta,S. Prabhakar,S. Kr Prabhakar,S. Pradhan,A. K. Roy,C. Sankhla,P. K. Sethi,Amy Shah,N. Shankar,R. Shukla,A. Sowani,R. Srinivasa,M. Varma,D. Vasudevan,P. Vavilikolanu Sreenivas,C. U. Velmurugendran,K. Vijayan,Ovidiu Bajenaru,A. Bulboaca,A. Campeanu,D. Chirileanu,D. Muresanu,C. Panea,C. D. Popescu,Mihaela Simu,M. Ticmeanu,Tania P. Avarello,Ubaldo Bonuccelli,Roberto Eleopra,Marco Onofrj,Rocco Quatrale +50 more
TL;DR: The addition of safinamide 50 mg/day or 100mg/day to l‐dopa in patients with PD and motor fluctuations significantly increased total on time with no or nontroublesome dyskinesia, decreased off time, and improved parkinsonism, indicating thatsafinamide improves motor symptoms and parkinsonistan without worsening dyskineia.
Journal ArticleDOI
Two-Year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease
Rupam Borgohain,József Attila Szász,Paolo Stanzione,Chandrashekhar Meshram,Mohit Bhatt,Dana Chirilineau,Fabrizio Stocchi,V. Lucini,R. Giuliani,Emma Forrest,Patricia Rice,R. Anand +11 more
TL;DR: This 2‐year, controlled study of add‐on safinamide in mid‐to‐late Parkinson's disease with motor fluctuations showed improvement in dyskinesia in patients at least moderately dyskinetic at baseline, and demonstrated significant clinical benefits in ON‐time (without troublesome dysKinesia), OFF‐time, activities of daily living, motor symptoms, quality of life, and symptoms of depression.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients†‡§
Fabrizio Stocchi,Rupam Borgohain,Marco Onofrj,Anthony H.V. Schapira,Mohit Bhatt,V. Lucini,R. Giuliani,R. Anand +7 more
TL;DR: Exploratory analysis of the primary endpoint for 100 mg/day demonstrated that the addition of safinamide to a stable dose of DA improves motor symptoms in early PD and warrants further investigation.
Journal ArticleDOI
Long‐term efficacy and safety of safinamide as add‐on therapy in early Parkinson's disease
Anthony H.V. Schapira,Fabrizio Stocchi,Rupam Borgohain,Marco Onofrj,Mohit Bhatt,P. Lorenzana,V. Lucini,R. Giuliani,R. Anand +8 more
TL;DR: Safinamide is an α‐aminoamide with both dopaminergic and non‐dopaminergic mechanisms of action in Phase III clinical development as a once‐daily add‐on to dopamine agonist (DA) therapy for early Parkinson's disease.